AFF1 and acute myeloid leukemia: We used RNA-seq from KMT2Ar ALL patients (Agraz-Doblas et al. 2019), AML patients with a range of chromosomal abnormalities (The Cancer Genome Atlas Research Network 2013), and hematopoietic stem and progenitor cell (HSPC) populations and B cells from normal fetal bone marrow (FBM) (O'Byrne et al. 2019) to generate individual patient-specific subnetworks derived from our SEM KMT2A-AFF1 GRN (Supplemental Fig. S3A; Methods).